Patients with Extended Treatment Benefit Showed an Objective Response Rate of 77.5% and a Median Duration of Response of 22.1 Months Overall Adverse Event Profile Observed Consistent with Known Safety Profile of Mirvetuximab with Minimal Cumulative Toxicities Study Outcomes in Patients with
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 1, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Kristen Harrington-Smith , Senior Vice President and Chief Commercial Officer (CCO), will be
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 1, 2022-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on October 31, 2022 , the compensation committee of the Company’s Board of Directors approved
Launch Preparations Completed Ahead of November 28, 2022 PDUFA Date Presentations at ESMO, IGCS, and ESGO Highlight Mirvetuximab’s Potential to Become New Standard of Care and Combination Agent of Choice in FRα-Positive Ovarian Cancer Initial Data from Pivotal Phase 2 CADENZA Study Demonstrated
ELAHERE is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer Indication Covers Patients with One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin ® Use VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the Companion Diagnostic to Identify Ovarian Cancer Patients
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 21, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Daniel Char , JD, has been appointed Senior Vice President and Chief Legal Officer.
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 1, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on November 30, 2022 , the compensation committee of the Company’s Board of Directors approved grants
Collaboration to Explore Potential of Complementary Mechanisms of Action for Novel Doublet WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 9, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced a clinical
Broad Anti-Leukemia Activity in Relapsed/Refractory and Frontline AML Presented in Oral Session Recommended Phase 2 Dose Well-Tolerated; Determination of Optimal Venclexta Duration Ongoing in Separate Cohorts WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 10, 2022-- ImmunoGen, Inc.
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 27, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will present at the upcoming 41 st Annual J.P.